Angeles Therapeutics is a next generation cell and immune therapy company based on the technology licensed from the laboratory of its founder Preet M. Chaudhary, MD, PhD (https://www.linkedin.com/in/preet-chaudhary-92774110/). Angeles has developed a novel CAR-T platform that provides physiological TCR signaling and overcomes most of the limitations of current generation CAR-T. Most importantly, our platform is highly effective against solid tumors. Angeles has also developed one of the largest portfolio of CAR-T in the world targeting more than 130 antigens covering cancer, infection and immune disorders. Our platform is fully compatible with autologous, allogeneic, universal and bispecific approaches. Angeles has recently entered a partnership with a global major pharmaceutical company and is looking for additional partnership opportunities for further development of its portfolio.